These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Takahashi Y; Fukusato T World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438 [TBL] [Abstract][Full Text] [Related]
10. Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. Lee C; Kim J; Jung Y Cells; 2019 Oct; 8(10):. PubMed ID: 31619023 [TBL] [Abstract][Full Text] [Related]
11. Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH. Pierantonelli I; Svegliati-Baroni G Transplantation; 2019 Jan; 103(1):e1-e13. PubMed ID: 30300287 [TBL] [Abstract][Full Text] [Related]
12. Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease. Babiy B; Ramos-Molina B; Ocaña L; Sacristán S; Burgos-Santamaría D; Martínez-Botas J; Busto R; Perna C; Frutos MD; Albillos A; Pastor Ó Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159318. PubMed ID: 37059386 [TBL] [Abstract][Full Text] [Related]
13. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. Gorden DL; Ivanova PT; Myers DS; McIntyre JO; VanSaun MN; Wright JK; Matrisian LM; Brown HA PLoS One; 2011; 6(8):e22775. PubMed ID: 21857953 [TBL] [Abstract][Full Text] [Related]
14. Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. Mato JM; Alonso C; Noureddin M; Lu SC World J Gastroenterol; 2019 Jun; 25(24):3009-3020. PubMed ID: 31293337 [TBL] [Abstract][Full Text] [Related]
15. Lipidomics in Nonalcoholic Fatty Liver Disease: Exploring Serum Lipids as Biomarkers for Pediatric Nonalcoholic Fatty Liver Disease. Draijer LG; Froon-Torenstra D; van Weeghel M; Vaz FM; Bohte AE; Holleboom AG; Benninga MA; Koot BGP J Pediatr Gastroenterol Nutr; 2020 Oct; 71(4):433-439. PubMed ID: 32947564 [TBL] [Abstract][Full Text] [Related]
16. Advances in paediatric nonalcoholic fatty liver disease: Role of lipidomics. Di Sessa A; Riccio S; Pirozzi E; Verde M; Passaro AP; Umano GR; Guarino S; Miraglia Del Giudice E; Marzuillo P World J Gastroenterol; 2021 Jul; 27(25):3815-3824. PubMed ID: 34321846 [TBL] [Abstract][Full Text] [Related]
17. Lipid mediators of liver injury in nonalcoholic fatty liver disease. Liangpunsakul S; Chalasani N Am J Physiol Gastrointest Liver Physiol; 2019 Jan; 316(1):G75-G81. PubMed ID: 30383414 [TBL] [Abstract][Full Text] [Related]
18. The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease. Lake AD; Novak P; Hardwick RN; Flores-Keown B; Zhao F; Klimecki WT; Cherrington NJ Toxicol Sci; 2014 Jan; 137(1):26-35. PubMed ID: 24097666 [TBL] [Abstract][Full Text] [Related]